| Date | Time | Source | Headline | Symbol | Company |
| 05/09/2006 | 8:00AM | PR Newswire (US) | Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/05/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Abstract to Be Presented at Heart Rhythm 2006 Scientific Sessions | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/25/2006 | 5:03PM | PR Newswire (US) | CV Therapeutics Reports 2006 First Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/18/2006 | 5:30PM | PR Newswire (US) | CV Therapeutics Secures Three Year Equity Financing Commitment | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/17/2006 | 6:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/13/2006 | 5:10PM | PR Newswire (US) | CV Therapeutics to Announce 2006 First Quarter Financial Results on Tuesday, April 25, 2006 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/24/2006 | 7:00AM | PR Newswire (US) | CV Therapeutics Launches Ranexa | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/10/2006 | 7:00AM | PR Newswire (US) | CV Therapeutics Begins Shipments of Ranexa to Wholesalers | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/03/2006 | 4:30PM | PR Newswire (US) | CV Therapeutics Announces Four Abstracts Accepted for Presentation at American College of Cardiology Scientific Sessions 2006 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/01/2006 | 4:03PM | PR Newswire (US) | CV Therapeutics Reports 2005 Fourth Quarter and Full Year Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/28/2006 | 5:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/15/2006 | 4:30PM | PR Newswire (US) | CV Therapeutics to Announce 2005 Fourth Quarter and Year End Financial Results on Wednesday, March 1, 2006 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/09/2006 | 7:00AM | PR Newswire (US) | CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as Planned Based on Interim Analysis | NASDAQ:CVTX | CV Therapeutics (MM) |
| 01/27/2006 | 5:14PM | PR Newswire (US) | FDA Approves Ranexa | NASDAQ:CVTX | CV Therapeutics (MM) |
| 01/13/2006 | 4:30PM | PR Newswire (US) | CV Therapeutics Appoints Joseph M. Davie, M.D., Ph.D. to Board of Directors | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/15/2005 | 5:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/09/2005 | 4:00PM | PR Newswire (US) | Maxygen Appoints Louis G. Lange to Its Board of Directors | NASDAQ:CVTX | CV Therapeutics (MM) |
| 11/16/2005 | 5:00PM | PR Newswire (US) | Data From Evaluation of Ranolazine in Chronic Angina (ERICA) Study Presented at American Heart Association Scientific Sessions 2 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 11/04/2005 | 7:00AM | PR Newswire (US) | CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2005 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 11/03/2005 | 5:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/25/2005 | 5:07PM | PR Newswire (US) | CV Therapeutics Withdraws European Marketing Application for Ranolazine | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/25/2005 | 5:02PM | PR Newswire (US) | CV Therapeutics Reports Third Quarter 2005 Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/20/2005 | 5:10PM | PR Newswire (US) | Data From CV Therapeutics Drug-Eluting Stent Program Presented at TCT Annual Scientific Symposium 2005 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/18/2005 | 8:00AM | PR Newswire (US) | CV Therapeutics to Announce 2005 Third Quarter Financial Results on Tuesday, October 25, 2005 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/02/2005 | 2:00PM | PR Newswire (US) | Regadenoson Phase 3 Data Presented as Late-Breaker at American Society of Nuclear Cardiology | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/15/2005 | 6:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/04/2005 | 6:55PM | PR Newswire (US) | The Lancet Publishes Data From ASCOT Study Showing Cardiovascular Benefits With Treatment Regimen That Includes Perindopril | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/04/2005 | 11:39AM | PR Newswire (US) | PREAMI Study Shows Perindopril Improved Cardiac Function in Elderly Patients Following a Heart Attack | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/30/2005 | 5:12PM | PR Newswire (US) | CV Therapeutics Announces Clinical Data on Perindopril From ASCOT, EUROPA, and PREAMI to Be Presented at ESC 2005 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/29/2005 | 8:00AM | PR Newswire (US) | Data From Regadenoson Phase 3 Study to Be Presented as Late Breaker at American Society of Nuclear Cardiology Scientific Session | NASDAQ:CVTX | CV Therapeutics (MM) |